RIGEL PHARMACEUTICALS INC

For the period ended Dec 31, 2024. Filed Mar 4, 2025.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2024 · Filed Mar 4, 2025

RIGL$43.91+4.4%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Statements of Stockholders’ Equity (Deficit)

** (In thousands, except number of shares)**


· · · · · · · · · · · · · · · · ·
· · · · · · · Additional · · Accumulated Other · · · · · Total
· · Common Stock (1) · · Paid-in · · Comprehensive · · Accumulated · · Stockholders’
· Shares · Amount · Capital (1) · Income (Loss) · Deficit · Equity (Deficit)
Balance as of January 1, 2022	17,160,175	$17	$1,354,345	$(102)	$(1,323,886)	$30,374
Net loss	—	—	—	—	(58,573)	(58,573)
Net change in unrealized loss on short-term investments	—	—	—	(51)	—	(51)
Issuance of common stock upon exercise of options and participation in Purchase Plan	158,016	—	2,124	—	—	2,124
Issuance of common stock upon vesting of restricted stock units (RSUs)	21,625	—	—	—	—
Stock-based compensation expense	—	—	12,510	—	—	12,510
Balance as of December 31, 2022	17,339,816	17	1,368,979	(153)	(1,382,459)	(13,616)
Net loss	—	—	—	—	(25,091)	(25,091)
Net change in unrealized loss on short-term investments	—	—	—	161	—	161
Issuance of common stock upon exercise of options and participation in Purchase Plan	99,196	—	1,049			1,049
Issuance of common stock upon vesting of RSUs	43,501	—	—			—
Stock-based compensation expense	—	—	8,853			8,853
Balance as of December 31, 2023	17,482,513	17	1,378,881	8	(1,407,550)	(28,644)
Net income	—	—	—	—	17,485	17,485
Net change in unrealized gain on short-term investments	—	—	—	2	—	2
Issuance of common stock upon exercise of options and participation in Purchase Plan	158,795	1	1,963	—	—	1,964
Issuance of common stock upon vesting of RSUs	68,908	—	—	—	—	—
Stock-based compensation expense	—	—	12,481	—	—	12,481
Balance as of December 31, 2024	17,710,216	$18	$1,393,325	$10	$(1,390,065)	$3,288

(1)	All share amounts in this column, including appropriate reclassifications between common stock and additional paid-in capital, have been restated to reflect the 1-for-10 reverse stock split effected on June 27, 2024 on a retroactive basis for the respective periods presented.

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.